Catalyst Watch: Earnings Deluge, Farnborough Airshow, Paris Olympics, and Trump Talks Crypto
Johnson & Johnson Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/19/2024 0.33% Goldman Sachs $160 → $155 Maintains Neutral 07/18/2024 19.74% TD Cowen $195 → $185
Peeling Back The Layers: Exploring AbbVie Through Analyst Insights
Analysts' ratings for AbbVie (NYSE:ABBV) over the last quarter vary from bullish to bearish, as provided by 10 analysts.The following table provides a quick overview of their recent ratings,
S&P Big Tech ETF Paces Decliners as S&P 500 Heads Toward Worst Week Since April
Abbott Labs Makes Marketing Push For New Glucose Monitors, Targets Health-Conscious Consumers
Abbott Laboratories (NYSE:ABT) CEO Robert Ford said the company will use a mix of TV advertisements and guerilla marketing to promote the U.S. launch of Lingo, its glucose monitoring device.This
Check Out What Whales Are Doing With PFE
Investors with a lot of money to spend have taken a bullish stance on Pfizer (NYSE:PFE).And retail traders should know.We noticed this today when the trades showed up on publicly available options
AbbVie Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/19/2024 24.78% BMO Capital $180 → $214 Maintains Outperform 07/11/2024 14.29% Morgan Stanley $191 → $19
Spotlight on Thermo Fisher Scientific: Analyzing the Surge in Options Activity
Investors with a lot of money to spend have taken a bearish stance on Thermo Fisher Scientific (NYSE:TMO).And retail traders should know.We noticed this today when the trades showed up on publicly
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Friday as Global IT Outage Recovery Begins
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2% and the actively traded Invesco QQQ Trust (QQQ) was 0.3% higher in Friday's premarket activity, as computer systems
Dividend Roundup: Goldman Sachs, Johnson & Johnson, Qualcomm, Caterpillar, and More
Eli Lilly's Famed Weight Loss Drug Zepbound Scores Chinese Approval
On Friday, China's National Medical Products Administration approved Eli Lilly And Co Tirzepatide for long-term weight management.
Dow Plunges Over 500 Points Following Unexpected Surge In US Jobless Claims
The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index moved to the "Neutral" zone on Thursday.U.S. stocks closed lower on Thursday, with the Dow Jones
Palantir, Netflix, Domino's Pizza, Eli Lilly, Tesla: Why These 5 Stocks Are On Investors' Radars Today
On Thursday, major U.S. stock indices were down, with the Dow Jones Industrial Average dropping nearly 1.3% to 40,665.03, the S&P 500 falling almost 0.8% to 5,544.59, and the Nasdaq decreasing 0.7% to 17,871.22.
Healthcare Stocks at an 'Inflection Point,' Analyst Says
J&J Ends Work on Addex Epilepsy Drug Candidate ADX71149: Report
Jobless Claims, Healthcare, Small Caps: Trading Takeaways
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
GLP-1 market leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) faced a significant selloff on Thursday, as new weight-loss drugs from rival pharmaceutical companies began threatening the dominance of their flagship products, Zepbound and Wegovy.
COVID Activity Is Elevated Across 26 States In Summer Surge, Biden Remains In Isolation: 3 Vaccine Stocks To Watch
More than half of the states in the U.S. are experiencing significant Covid-19 activity in wastewater, and President Joe Biden remains in isolation after announcing Wednesday he caught the virus for
Merck Gets Legal Victory As Appeals Court Dismisses Shingles Vaccine Some 1,200 Lawsuits
Merck & Co Inc (NYSE:MRK) has reportedly secured a significant legal victory as the 3rd U.S. Circuit Court of Appeals upheld the dismissal of nearly 1,200 lawsuits concerning its Zostavax shingles
Why Are Abbott Laboratories Shares Trading Lower?
Shares of Abbott Laboratories (NYSE:ABT) are trading lower on Thursday following the company's second-quarter 2024 financial results.What's Going On: Abbott reported second-quarter sales of $10.377